Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Elisa Tripodi"'
Autor:
Stefania Perotto, Jessica Mauro, Chiara Borghi, Elisa Tripodi, Alessandra Surace, Marco Pagano, Giuseppe Di Guardia, Alessandro Buda
Publikováno v:
Vaginal and vulvar cancer.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3734216c2797fac1d47caf54350982cf
https://doi.org/10.1136/ijgc-2022-esgo.942
https://doi.org/10.1136/ijgc-2022-esgo.942
Autor:
Alessandro Buda, Martina Borghese, Andrea Puppo, Stefania Perotto, Antonia Novelli, Chiara Borghi, Elena Olearo, Elisa Tripodi, Alessandra Surace, Enrica Bar, Giovanni Scambia, Francesco Fanfani
Publikováno v:
Cancers, Vol 14, Iss 797, p 797 (2022)
Nowadays, the optimal management of patients with cervical cancers measuring 2–4 cm desiring to maintain fertility is still uncertain. In this systematic review, we assessed the reliability of neoadjuvant chemotherapy (NACT) prior to fertility-spar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4c3bc3b51da5c359060f3f3954296ac
https://www.mdpi.com/2072-6694/14/3/797
https://www.mdpi.com/2072-6694/14/3/797
Autor:
Elisa Tripodi, Stefano Lepori, Giuseppa Maltese, Gennaro Cormio, Daniela Rubino, Giorgio Valabrega, Ilaria Sabatucci, Domenica Lorusso, Ugo De Giorgi
Publikováno v:
International Journal of Gynecologic Cancer. 29:153-157
BackgroundPegylated liposomal doxorubicin (PLD) is an active and well-tolerable treatment in ovarian cancer relapse, either alone or in combination with other drugs. No data are available on the possibility to rechallenge PLD treatment in long surviv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::12c177ab7f5fd5e4627e116121a69dae
https://doi.org/10.1136/ijgc-2018-000034
https://doi.org/10.1136/ijgc-2018-000034
Publikováno v:
Translational Cancer Research
Pregnancy-associated breast cancer (PABC) is defined as breast cancer develops either during or within 1 year after pregnancy, it is a rare disease arising in 1:3,000 to 1:10,000 pregnant women. Prognosis of this tumor is influenced by local or syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18256826d676e6c9e3ab9ee19fa14caf
http://europepmc.org/articles/PMC8797300
http://europepmc.org/articles/PMC8797300
Autor:
Elisa Tripodi, Francesco Raspagliesi, Stefano Lepori, Giorgio Bogani, Ilaria Sabatucci, Domenica Lorusso, Giuseppa Maltese
Publikováno v:
Drug Design, Development and Therapy
Epithelial ovarian cancer is the sixth most common cancer among women worldwide and the first cause of death among gynecological malignancies. Most of the patients present recurrent disease and unfortunately cannot be cured. The unsatisfactory result
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44e6f45709388589cf306b968c302690
http://europepmc.org/articles/PMC5983012
http://europepmc.org/articles/PMC5983012
Autor:
Ilaria Sabatucci, Domenica Lorusso, Elisa Tripodi, Giorgio Bogani, Giuseppa Maltese, Stefano Lepori
Publikováno v:
Expert Opinion on Pharmacotherapy. 19:765-771
Approximately 50% of high-grade serous ovarian cancers present a deficiency in the pathways involved in homologous recombination (HR). PARP inhibitors prevent single-strand DNA damage repair and determine a progression of the defect towards double-st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66623cec574528faae5e5a5b59cc10b0
https://doi.org/10.1080/14656566.2018.1464557
https://doi.org/10.1080/14656566.2018.1464557
Autor:
Stefano Lepori, Elisa Tripodi, Francesco Raspagliesi, Domenica Lorusso, Giuseppa Maltese, Giorgio Bogani, C. Fontanella
Publikováno v:
Expert Opinion on Drug Safety. 16:687-696
Recurrence is a common event in endothelial ovarian cancer (EOC) patients, and the choice of the most appropriate treatment is driven by the platinum-free interval, molecular characteristics of the disease such as BRCA mutational status, previous tre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cd1b5a87d99a4c90148b08b7ea382c28
https://doi.org/10.1080/14740338.2017.1325871
https://doi.org/10.1080/14740338.2017.1325871
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 29(2)
BackgroundCervical cancer is a common malignancy among women and, when recurring, presents a dismal prognosis. After platinum failure, second-line treatments report response rates ranging from 3–15%, a median progression-free survival of about 3 mo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ef46fbf089ae2345ab4e680ecdb9cbc
https://pubmed.ncbi.nlm.nih.gov/30636709
https://pubmed.ncbi.nlm.nih.gov/30636709
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ilaria Sabatucci, Caterina Fontanella, Domenica Lorusso, Antonino Ditto, Mauro Signorelli, Giorgio Bogani, Elisa Tripodi, B. Pappalardi, Cono Scaffa, Francesco Rapagliesi, Stefano Lepori, Fabio Martinelli, Giuseppa Maltese, Annamaria Cerrotta
Publikováno v:
Oncology. 95(4)
Background: Chemoradiotherapy (CRT) is the standard of care for locally advanced cervical cancer (LACC). Pre-treatment lymph nodes (LN) assessment may have an important therapeutic role. CRT followed by adjuvant chemotherapy increased progression fre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1943f91e94315b81563cea0c8e692df9
https://pubmed.ncbi.nlm.nih.gov/29920481
https://pubmed.ncbi.nlm.nih.gov/29920481